Literature DB >> 11352959

Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma.

K M Acland1, C Healy, E Calonje, M O'Doherty, T Nunan, C Page, E Higgins, R Russell-Jones.   

Abstract

PURPOSE: Sentinel node biopsy (SNB) is a surgical technique for detecting micrometastatic disease in the regional draining nodes. 2-fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scanning is an imaging technique that can detect clinically undetectable metastases. This prospective study was undertaken to compare the sensitivity of FDG-PET scanning with SNB in the detection of micromatastatic malignant melanoma. PATIENTS AND METHODS: Fifty consecutive patients (23 women, 27 men; mean age, 53 years) with primary melanoma >1 mm thick or lymphatic invasion were recruited (mean, 2.41 mm). Primary lesions had been narrowly excised (<1 cm). Patients underwent PET scanning followed by SNB, using a dual technique. Preoperative lymphoscintigraphy was used to identify the draining basin. Lymph nodes were examined histologically and immunostained for S100 and HMB 45.
RESULTS: The sentinel node (SN) was identified in all patients. Fourteen patients (28%) had positive SNBs, including eight patients with melanoma <1.5 mm thick. In none of these 14 patients did PET scans identify metastatic disease in the SN or draining basin. In seven patients, the PET scans were positive in other locations, and in four cases, this was suspicious of metastatic disease. However, no patient has developed recurrent melanoma (mean follow-up, 15 months). All patients with positive SNBs underwent therapeutic lymph node dissection. Further lymph node involvement was found in two patients (primary lesions, 1.3 mm and 3.5 mm thick).
CONCLUSION: This study demonstrates the limitations of FDG-PET scanning in staging patients with primary melanoma. SNB is the only reliable method for identifying micrometastatic disease in the regional draining node.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11352959     DOI: 10.1200/JCO.2001.19.10.2674

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  21 in total

Review 1.  Positron emission tomography for benign and malignant disease.

Authors:  Anthony Visioni; Julian Kim
Journal:  Surg Clin North Am       Date:  2011-02       Impact factor: 2.741

Review 2.  PET and SPECT imaging of melanoma: the state of the art.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quanyong Luo; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-30       Impact factor: 9.236

3.  A new animal model for the imaging of melanoma: correlation of FDG PET with clinical outcome, macroscopic aspect and histological classification in Melanoblastoma-bearing Libechov Minipigs.

Authors:  Raphaël Boisgard; Silvia Vincent-Naulleau; Jean-Jacques Leplat; Stephan Bouet; Catherine Le Chalony; Yves Tricaud; Vratislav Horak; Claudine Geffrotin; Gérard Frelat; Bertrand Tavitian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-08       Impact factor: 9.236

4.  Targeted melanoma imaging and therapy with radiolabeled alpha-melanocyte stimulating hormone peptide analogues.

Authors:  T Quinn; X Zhang; Y Miao
Journal:  G Ital Dermatol Venereol       Date:  2010-04       Impact factor: 2.011

5.  How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning: the case of lymph node staging in melanoma.

Authors:  G S Mijnhout; O S Hoekstra; A van Lingen; P J van Diest; H J Adèr; A A Lammertsma; R Pijpers; S Meijer; G J J Teule
Journal:  J Clin Pathol       Date:  2003-04       Impact factor: 3.411

Review 6.  Peptide-targeted radionuclide therapy for melanoma.

Authors:  Yubin Miao; Thomas P Quinn
Journal:  Crit Rev Oncol Hematol       Date:  2008-04-02       Impact factor: 6.312

7.  A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy.

Authors:  Steven E Finkelstein; Jorge A Carrasquillo; John M Hoffman; Barbara Galen; Peter Choyke; Donald E White; Steven A Rosenberg; Richard M Sherry
Journal:  Ann Surg Oncol       Date:  2004-07-12       Impact factor: 5.344

8.  Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B.

Authors:  Klaus Strobel; Jeannine Skalsky; Victor Kalff; Katrin Baumann; Burkhardt Seifert; Helen Joller-Jemelka; Reinhard Dummer; Hans C Steinert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03-28       Impact factor: 9.236

9.  Design, synthesis, and preliminary in vitro and in vivo evaluation of N-(2-diethylaminoethyl)-4-[18F]fluorobenzamide ([18F]-DAFBA): a novel potential PET probe to image melanoma tumors.

Authors:  Sudha Garg; Kanchan Kothari; Shankar R Thopate; Aniruddha K Doke; Pradeep K Garg
Journal:  Bioconjug Chem       Date:  2009-03-18       Impact factor: 4.774

10.  Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma.

Authors:  Felisa Jiménez-Requena; Roberto C Delgado-Bolton; Cristina Fernández-Pérez; Sanjiv S Gambhir; Judy Schwimmer; José M Pérez-Vázquez; José L Carreras-Delgado
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-02       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.